8-K: Passage Bio Reports Full-Year 2023 Financial Results and Provides Business Update, Appoints New CFO

Passage Bio announced its 2023 financial results, highlighted progress in its FTD-GRN clinical trial, and appointed Kathleen Borthwick as Chief Financial Officer.

Summary

• Passage Bio reported its financial results for the year ended December 31, 2023, showing a net loss of $102.1 million, or $1.86 per share.
• The company's cash, cash equivalents, and marketable securities totaled $114.3 million as of December 31, 2023, which is expected to fund operations into Q4 2025.
• Research and development expenses were $61.4 million for the year, down from $86.1 million in 2022.
• General and administrative expenses were $41.6 million for the year, compared to $49.3 million in 2022.
• The company is progressing its upliFT-D trial for PBFT02 in frontotemporal dementia with granulin mutations (FTD-GRN), with the first European site now activated.
• Initial data from the first three patients in Cohort 1 of the FTD-GRN program showed that PBFT02 raised CSF progranulin to supraphysiologic levels.
• Passage Bio is also exploring new indications for PBFT02, including FTD-C9orf72, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.
• Kathleen Borthwick was appointed Chief Financial Officer, effective March 1, 2024, after serving as Interim CFO.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical data and a strong cash position, but the significant net loss and ongoing clinical development risks temper the overall sentiment.

Positives

• The company has a strong cash position, expected to fund operations into Q4 2025.
• Initial clinical data for PBFT02 in FTD-GRN is encouraging, showing supraphysiologic levels of CSF progranulin.
• The company is expanding the potential use of PBFT02 into additional neurodegenerative diseases.
• The appointment of a permanent CFO provides stability to the financial leadership.
• The company is actively pursuing out-licensing opportunities for its pediatric programs.

Negatives

• The company reported a significant net loss of $102.1 million for the year ended December 31, 2023.
• Cash reserves decreased from $189.6 million in 2022 to $114.3 million in 2023.
• Research and development expenses, while down from the previous year, remain substantial at $61.4 million.
• The company is still in the clinical stage and has not yet generated revenue from product sales.

Risks

• The company is dependent on the success of its clinical trials, which are subject to regulatory approval and potential delays.
• There are risks associated with clinical trials, including unexpected safety concerns and the possibility that positive results may not be replicated.
• The company relies on third parties for the development and manufacture of its product candidates.
• The company faces competition from other companies developing treatments for neurodegenerative diseases.
• The company's cash runway is dependent on its ability to manage expenses and achieve milestones.

Future Outlook

Passage Bio anticipates a catalyst-rich 2024, with key milestones including completing dosing for Cohort 1 patients in the FTD-GRN trial, reporting 6-month safety and biomarker data, and obtaining regulatory feedback on the clinical pathway for treating FTD-C9orf72 and ALS patients. The company expects its current cash balance to fund operations into Q4 2025.

Management Comments

• Will Chou, M.D., president and chief executive officer of Passage Bio, stated that the company achieved a significant milestone by announcing encouraging data from three patients in Cohort 1 of their FTD-GRN program.
• Will Chou also mentioned that the company is optimistic about expanding the application of PBFT02 beyond FTD-GRN and into new indications.
• The company is eager to bring treatments closer to improving patient outcomes across neurodegenerative diseases.

Industry Context

Passage Bio is operating in the competitive field of genetic medicines for neurodegenerative diseases. The company's focus on progranulin-raising therapies aligns with the growing understanding of the role of progranulin in various neurodegenerative conditions. The expansion into new indications like FTD-C9orf72, ALS, and Alzheimer's disease reflects a broader trend in the industry to target common pathways across multiple diseases.

Comparison to Industry Standards

• Passage Bio's approach of using AAV vectors for gene therapy is consistent with industry trends, with companies like Sarepta Therapeutics and BioMarin also using AAV vectors for gene therapies.
• The company's focus on rare neurodegenerative diseases is similar to companies like Ultragenyx and REGENXBIO, which also target rare genetic disorders.
• The reported cash runway into Q4 2025 is a positive sign, as many biotech companies face challenges in securing funding for long-term development.
• The initial clinical data showing supraphysiologic levels of CSF progranulin is promising and could position PBFT02 as a potential best-in-class treatment, but further data is needed to confirm this.
• The company's strategy of out-licensing its pediatric programs is a common approach in the biotech industry to focus resources on core programs.

Management Changes

Stakeholder Impact

• Shareholders may view the clinical progress and extended cash runway positively.
• Employees may be encouraged by the company's progress and financial stability.
• Patients and families affected by neurodegenerative diseases may be hopeful about the potential of PBFT02.
• Creditors may be reassured by the company's cash position and ability to fund operations.

Next Steps

• Initiate dosing for Cohort 2 FTD-GRN patients in 1H 2024.
• Report 6-month safety and biomarker data from Cohort 1 patients in 2H 2024.
• Announce 12-month follow-up data from Cohort 1 patients in 1H 2025.
• Report initial safety and biomarker data from Cohort 2 patients in 1H 2025.
• Obtain regulatory feedback on the pathway to treating FTD-C9orf72 and ALS patients with PBFT02 in 2H 2024.

Key Dates

Keywords

Passage Bio, PBFT02, FTD-GRN, Neurodegenerative Diseases, Gene Therapy, Clinical Trial, Progranulin, CFO, Financial Results, Biomarkers